FLOVENT 250mcg

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Asthma

Phase 4

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

CompletedNCT01462344

GlaxoSmithKlineAsthma

Start: 2011-11-17End: 2015-11-03Updated: 2018-08-06

SAS115359: A 6-month Study to Assess the Safety and Benefit of Inhaled Fluticasone Propionate/Salmeterol Combination Compared With Inhaled Fluticasone Propionate in the Treatment of Adolescents and Adults (12 Years of Age and Older) With Asthma.

CompletedNCT01475721

GlaxoSmithKlineAsthma

Start: 2011-11-18End: 2015-06-23Updated: 2018-08-06

Related Papers

Insights from the AUSTRI study on reliever use before and after asthma exacerbations

The Journal of Allergy and Clinical Immunology In Practice2022-04-099 citations

AUSTRI and VESTRI LABA Safety studies subgroup analysis of asthma exacerbations and SAEs comparing FSC and FP by ICS dose

2017-09-01

Safety of Adding Salmeterol to Fluticasone Propionate in Children with Asthma

New England Journal of Medicine2016-08-31134 citations

Serious Asthma Events with Fluticasone plus Salmeterol versus Fluticasone Alone

New England Journal of Medicine2016-03-06155 citations